Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Postmarketing surveillance study of tocilizumab in Japanese patients with rheumatoid arthritis

Trial Profile

Postmarketing surveillance study of tocilizumab in Japanese patients with rheumatoid arthritis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Chugai Pharmaceutical

Most Recent Events

  • 13 Jun 2015 Results of 3-year extension study in 5573 patients presented at the 16th Annual Congress of the European League Against Rheumatism.
  • 11 Nov 2011 New trial record
  • 09 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top